openPR Logo
Press release

Fanconi’s Anemia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Elixirgen Scientific, Abeona Therapeutics

04-15-2019 12:39 PM CET | Health & Medicine

Press release from: Fanconi’s Anemia Therapeutics-Pharma Proff

Fanconi’s Anemia Therapeutics- Pipeline Analysis 2018,

Fanconi anemia is an inherited disease, caused by mutations in FA genes. These genes provide instructions to repair certain types of DNA damage in the human body. The cells of healthy people often repair DNA damage; however, cells affected by Fanconi anemia are not able to repair damages.

Download the sample report at: https://www.pharmaproff.com/request-sample/1038

The symptoms associated with the disease are decreased blood cell counts, bone problems, vitiligo, deafness, eye problems, short height, small head, small testicles and genital changes. The disease can be diagnosed by bone marrow biopsy, complete blood count test, hearing test, computed tomography (CT) scan and magnetic resonance imaging (MRI).

Get the detailed analysis at: https://www.pharmaproff.com/report/fanconis-anemia-therapeutics-pipeline-analysis

The disease can be treated by growth factors, hormone therapy, antibiotics and blood transfusions. According to the data published by the National Organization for Rare Disorders, the incidence rate of Fanconi anemia is estimated to be around 1 in 136,000 births.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1038

This condition is more common among people of Ashkenazi Jewish descent, the Roma population of Spain, and black South Africans. Some of the major companies having therapeutic agents for the treatment of Fanconi's anemia in their pipeline include Elixirgen Therapeutics LLC, Abeona Therapeutics, Inc. and others. For instance, Abeona Therapeutics Inc. is in the process of developing ABO-301 gene therapy for the treatment of Fanconi anemia.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fanconi’s Anemia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Elixirgen Scientific, Abeona Therapeutics here

News-ID: 1703153 • Views:

More Releases for Fanconi

Fanconi Anemia Market Innovations, Key Players and Growth Opportunities
Fanconi Anemia (FA) is a rare, inherited disorder that leads to bone marrow failure, chromosomal instability, and an increased risk of cancers. FA is typically diagnosed in children and can lead to severe complications such as leukemia, solid tumors, and growth abnormalities. This condition is caused by mutations in specific genes responsible for DNA repair, leading to defective cell functioning and high levels of genetic damage. Individuals with FA often
Renal Fanconi Syndrome Market Forecast 2025-2034: Comprehensive Analysis And Gro …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Projected Growth of the Renal Fanconi Syndrome Market? In recent times, the market size for renal fanconi syndrome has experienced sustained growth. The market is forecasted to increase from $0.53 billion in 2024 to $0.55 billion in 2025, with a compound annual growth rate (CAGR) of 4.0%. Several factors
Fanconi Anemia Treatment Market: Navigating Rare Disease Therapeutics
The fanconi anemia treatment market was valued at approximately USD 1.5 billion in 2023 and is expected to reach USD 3.2 billion by 2033, growing at a CAGR of around 8.1% from 2024 to 2033. The Fanconi Anemia (FA) treatment market represents a specialized segment within the rare disease therapeutics landscape, characterized by significant unmet medical needs and emerging therapeutic innovations. Fanconi Anemia, a rare inherited bone marrow failure syndrome affecting
Fanconi Anemia Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Fanconi Anemia Pipeline Insight 2024" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Fanconi Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Fanconi Anemia Research. Learn more about
Fanconi Anemia Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Fanconi Anemia Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies current
Renal Fanconi Syndrome Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Renal Fanconi Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Renal Fanconi Syndrome, historical and forecasted epidemiology as well as the Renal Fanconi Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Renal Fanconi Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Renal